Cat. No.: HY-127146

Platensimycin

Name: Platensimycin
Brand: MedChemExpress
SKU: HY-127146
Price: 816.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

고객리뷰

Based on 1 publication(s) in Google Scholar

APOL1-IN-1 is a natural product antibiotic and selective FabF inhibitor discovered in Streptomyces platensis. Platensimycin exhibits IC₅₀ values of 48 nM and 160 nM against Staphylococcus aureus and Escherichia coli FabF, respectively. Platensimycin preferentially recognizes the acyl-enzyme conformation of FabF, occupies the malonyl-binding subsite, and competes with malonyl-ACP, thereby inhibiting bacterial fatty acid elongation. Platensimycin is useful for research on bacterial fatty acid biosynthesis and Gram-positive bacterial infections.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No.: 835876-32-9
화학식: C₂₄H₂₇NO₇
분자량:441.47

보관:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Platensimycin Chemical Structure

CAS No.: 835876-32-9

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (1)
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All Antibiotic Isoforms :

In Vitro

Platensimycin inhibits S. aureus and E. coli FabF with IC₅₀ values of 48 nM and 160 nM, respectively, while its IC₅₀ against S. aureus FabH is 67 μM, indicating selective inhibition of FabF^[1].
Platensimycin inhibits cellular lipid biosynthesis in S. aureus with an IC₅₀ of 0.1 μg/mL, whereas it does not significantly inhibit DNA, RNA, protein, or cell wall biosynthesis at concentrations up to 500 μg/mL^[1].
Platensimycin inhibits cellular lipid biosynthesis in S. pneumoniae with an IC₅₀ of 0.8 μg/mL^[1].
Platensimycin inhibits the fatty acid synthase system in the S. aureus FASII cell-free gel elongation assay with an IC₅₀ of 0.2 μg/mL^[1].
Platensimycin exhibits antibacterial activity against MSSA, MRSA, VISA, VRE, and S. pneumoniae, with MIC values up to 0.5, 0.5, 0.5, 0.1, and 1 μg/mL, respectively; its MIC against wild-type E. coli is >64 μg/mL, whereas its MIC against efflux-negative E. coli (tolC) is 16 μg/mL^[1].
Platensimycin (0.5-64 μg/mL; 16 h) exhibits MICs of 1, 0.5, and 0.5 μg/mL against S. aureus ATCC 29213, clinical MSSA, and MRSA strains, respectively^[3].
Platensimycin retains antibacterial activity against 4 clinical MSSA and 45 clinical MRSA isolates, with an MIC of 1.0 μg/mL^[3].
Platensimycin (0.125-64 μg/mL; 12 or 24 h) inhibits MRSA growth, and growth inhibition is observed at concentrations below 2 μg/mL^[4].
Platensimycin has an MIC of 1 μg/mL against extracellular MRSA, whereas its MIC against intracellular MRSA is >128 μg/mL^[4].
Platensimycin (2-8 μg/mL; 24 h) inhibits MRSA biofilm formation^[4].
The permeability coefficients of PLGA/PTM and PAMAM/PTM nanoparticles (100 μM) in Caco-2 cell monolayers (4.7 × 10⁻⁷ cm s⁻¹ and 6.0 × 10⁻⁷ cm s⁻¹, respectively) increase compared with free PTM^[5].
Platensimycin (0.5 μg/mL; 24 h) reduces biofilm formation by 88.3% in S. aureus ATCC 29213^[5].
Platensimycin binds to the acyl-enzyme state of FabF with a binding IC₅₀ of 19 nM, and the binding signal increases 19-fold relative to apo FabF after formation of the acyl-enzyme intermediate^[1].
Platensimycin (100 μg/mL) does not significantly reduce cell viability in RAW 264.7 cells^[5].
The apparent permeability coefficient P_app of platensimycin in the Caco-2 monolayer model is 2.4 × 10^-7 cm/s^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	AUC_0-t	AUC_0-∞	MRT_0-t	MRT_0-∞	T_1/2	T_max	CL_z/F	V_z/F	C_max
Rat^[4]	20 mg/kg	i.p.	30.66 μg/mL·h	35.94 μg/mL·h	0.76 h	0.23 h	0.69 h	0.33 h	0.56 L/h/kg	0.56 L/kg	28.47 μg/mL
Rat^[5]	20 mg/kg	i.p.	59.12 mg·h/L	74.32 mg·h/L	0.79 h	1.32 h	0.89 h	0.2 h	0.27 L/h/kg	0.35 L/kg	54.3 mg/L

In Vivo

Platensimycin (50, 100, 150 μg/h; continuous i.v. infusion; 24 h) reduces renal bacterial burden in mice with disseminated S. aureus infection, with 100 and 150 μg/h decreasing viable counts by 4-5 log and rendering 20% and 40% of kidneys free of detectable viable bacteria, respectively^[1].
Platensimycin (10 mg/kg; i.p.; at 1 and 5 h after bacterial challenge) does not maintain survival in MRSA peritonitis C57BL/6J mice, and none of the PTM group mice survive to the observation endpoint^[3].
Platensimycin (50 mg/kg; i.p.; at 1 and 5 h after bacterial challenge) achieves a 50% survival rate in a mouse model of peritonitis infected with 2.5 × 10⁷ CFU MRSA^[4].
Platensimycin (20 mg/kg; i.p.; at 1 and 5 h after bacterial challenge) results in survival of all animals in the 1.25 × 10⁷ CFU MRSA peritonitis mouse model, whereas in the more severe model with 2.5 × 10⁷ CFU, no mice survive beyond day 2^[4].
Platensimycin (10 mg/kg; i.p.; twice after MRSA challenge) does not maintain survival in C57BL/6J mice with 2.5 × 10⁷ CFU MRSA peritonitis, and none of the 5 mice survive beyond 24 h^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice^[1]
Dosage:

50, 100, 150 μg/h
Administration:

i.v.; 24 h
Result:

Produced a 4-5 log reduction in viable kidney bacteria at 100 and 150 μg/h.
Yielded no detectable viable bacteria in 20% and 40% of kidneys at 100 and 150 μg/h, respectively.

Animal Model:

C57BL/6J (six-week-old)^[3]
Dosage:

10 mg/kg
Administration:

i.p.; at 1 and 5 h post-infection
Result:

Failed to rescue any mice from lethal MRSA peritonitis, with a 0% survival rate.

Animal Model:

C57BL/6J (female, 6-8 weeks old, MRSA-induced acute peritonitis)^[5]
Dosage:

10 mg/kg
Administration:

wice after MRSA challenge
Result:

None of five mice survived beyond 24 h.

Animal Model:

C57BL/6J mice (6-8 weeks old, 18-21 g)^[4]
Dosage:

20 mg/kg
Administration:

i.p.; administered at 1 h and 5 h post-infection
Result:

No mice survived beyond day 2.
Produced survival of all mice.

Chemical Information

CAS No. 835876-32-9
Appearance Solid
분자량 441.47
화학식 C₂₄H₂₇NO₇
Color White to off-white
SMILES

O=C(O)C1=CC=C(O)C(NC(CC[C@]([C@@]2([H])[C@]34C[C@]5([H])[C@@](C4)(C)O[C@@]2([H])C5)(C)C(C=C3)=O)=O)=C1O
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 Apr 7.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (297 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang J, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature. 2006 May 18;441(7091):358-61.

[2]. Cao D, Yang J, Deng Y, Su M, Wang Y, Feng X, Xiong Y, Bai E, Duan Y, Huang Y. Discovery of a mammalian FASN inhibitor against xenografts of non-small cell lung cancer and melanoma. Signal transduction and targeted therapy. 2022 Aug 24;7(1):273.

[3]. Deng Y, et al. Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo. Journal of medicinal chemistry. 2019 Jul 25;62(14):6682-6693.

[4]. Wang Z, Liu X, Peng Y, Su M, Zhu S, Pan J, Shen B, Duan Y, Huang Y. Platensimycin-encapsulated liposomes or micelles as biosafe nanoantibiotics exhibited strong antibacterial activities against methicillin-resistant Staphylococcus aureus infection in mice. Molecular Pharmaceutics. 2020 Jun 10;17(7):2451-62.

[5]. Liu X, et al. Platensimycin-Encapsulated Poly(lactic--glycolic acid) and Poly(amidoamine) Dendrimers Nanoparticles with Enhanced Anti-Staphylococcal Activity . Bioconjugate chemistry. 2020 May 20;31(5):1425-1437.

[6]. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, Ball RG, Basilio A, Genilloud O, Diez MT. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. Journal of the American Chemical Society. 2006 Sep 13;128(36):11916-20.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Platensimycin

1 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Platensimycin

Publications Citing Use of MedChemExpress (MCE) Platensimycin

All Antibiotic Isoforms